Contineum Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.1%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$1.65next fiscal year
Monitoring Framework
Key Performance Indicators
PIPE-791 Clinical Trial Progress (PROPEL-IPF Phase 2) QuarterlyTarget: Top-line results expected in the second half of 2026
PIPE-307 Phase 2 Depression Trial Readout QuarterlyTarget: Top-line results expected in mid-2026
Cash Runway Quarterly246.3MTarget: Sufficient to fund operations through mid-2029
Watch Items
- PIPE-307 Phase 2 clinical trial results in Major Depressive Disorder (MDD)Trigger: Top-line data release in mid-2026Action: Evaluate efficacy and safety profile to determine if J&J (Janssen) will exercise its option for further development.
- PIPE-791 Phase 2 clinical trial results in Idiopathic Pulmonary Fibrosis (IPF)Trigger: Top-line data release in H2 2026Action: Assess primary and secondary endpoints to validate LPA1R mechanism and plan for registrational Phase 3 trials.
- Strategic funding for deferred pipeline programsTrigger: Securing specific external funding or partnershipsAction: Re-initiate clinical development of the PIPE-791 Progressive MS (PrMS) program and the CTX-343 program.
Research as of 19 Jun 2026